Idelalisib – Uses, Dosage, Side Effects, Interation

Last updated: February 8, 2026Reviewed date: February 8, 2026Reading time: 67 min read
Patient Tools

Read, save, and share this guide

Use these quick tools to make this medical article easier to read, print, save, or share with a family member.

On this page11 sections

Article Summary

Idelalisib is an oral kinase inhibitor that is approved for use in combination with rituximab in relapsed or refractory chronic lymphocytic leukemia (CLL) and as monotherapy for relapsed follicular B cell, small lymphocytic lymphoma, and indolent non-Hodgkin lymphoma. Idelalisib is associated with a high rate of serum enzyme elevations during therapy and has been reported to cause clinically apparent acute liver injury that can be...

Key Takeaways

  • This article explains Mechanism of Action in simple medical language.
  • This article explains Indications in simple medical language.
  • This article explains Contraindications in simple medical language.
  • This article explains Dosage in simple medical language.
Before reading

RX Patient Tools

Use these quick guides before reading the article, or return to them when you need help preparing questions for a doctor.

Start here Choose the right pathway for symptoms, reports, medicines, or urgent warning signs. Disease article roadmap Read this topic step by step: meaning, symptoms, warning signs, diagnosis, treatment, prevention, and follow-up. Treatment planner Prepare questions about treatment choices, benefits, risks, side effects, and follow-up. Family & caregiver guide Organize symptoms, reports, medicines, questions, and follow-up safely. Nutrition & diet guide Prepare food, hydration, supplement, and medicine-timing questions safely. Prevention guide Organize risk factors, protective habits, screening, and warning signs. Recovery guide Prepare a safe plan for activity, rehabilitation, warning signs, and follow-up.
Educational health guideWritten for patient understanding and clinical awareness.
Reviewed content workflowUse writer and reviewer profiles for stronger trust.
Emergency safety firstUrgent warning signs are highlighted below.
Choose your reading view

Patient View highlights a simple learning journey. Clinical View reveals structure, evidence, and editorial completeness.

Definition

Idelalisib is an oral kinase inhibitor that is approved for use in combination with rituximab in relapsed or lymphocytic (CLL) and as monotherapy for relapsed follicular B cell, small lymphocytic , and indolent non-Hodgkin lymphoma. Idelalisib is associated with a high rate of serum enzyme elevations during therapy and has been reported to cause clinically apparent injury that can be and even fatal.

Idelalisib is an orally bioavailable, small-molecule inhibitor of the delta isoform of the 110 kDa catalytic subunit of class I phosphoinositide-3 kinase (PI3K) with potential immunomodulating and antineoplastic activities. Idelalisib inhibits the production of the second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3), preventing the activation of the PI3K signaling pathway and inhibiting cell proliferation, motility, and survival. Unlike other isoforms of PI3K, PI3K-delta is expressed primarily in hematopoietic lineages. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells.

Idelalisib is a member of the class of quinazolines that is 5-fluoro-3-phenylquinazolin-4-one in which the hydrogen at position 2 is replaced by a (1S)-1-(3H-purin-6-ylamino)propyl group. used for the treatment of refractory indolent non-Hodgkin’s lymphoma and relapsed chronic lymphocytic leukemia. It has a role as an antineoplastic agent, an apoptosis inducer, and an EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor. It is a member of purines, an organofluorine compound, a member of quinazolines, an aromatic amine, and a secondary amino compound.

Mechanism of Action

Idelalisib specifically inhibits P110δ, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer. In contrast to the other class IA PI3Ks p110α and p110β, p110δ is principally expressed in leukocytes (white blood cells) and is important for the function of T cells, B cell, mast cells and neutrophils. By inhibiting this enzyme, idelalisib induces apoptosis of cells and inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and type 4 signalling, which are involved in trafficking and homing of B-cells to the and . Treatment of lymphoma cells with idelalisib has been shown to result in inhibition of chemotaxis and adhesion, and reduced cell viability.

or

Idelalisib is an inhibitor of PI3Kdelta kinase, which is expressed in normal and malignant B-cells. Idelalisib induced apoptosis and inhibited proliferation in cell lines derived from malignant B-cells and in primary tumor cells. Idelalisib inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and the CXCR4 and CXCR5 signaling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone marrow. Treatment of lymphoma cells with idelalisib resulted in inhibition of chemotaxis and adhesion, and reduced cell viability.

Indications

  • Idelalisib is indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior therapies.
  • Zydelig is indicated in combination with an anti‑CD20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic (CLL): who have received at least one prior therapy, or as first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies.
  • Zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (FL) that is refractory to two prior lines of treatment.
  • Idelalisib is an oral kinase inhibitor that is approved for use in combination with rituximab in relapsed or refractory chronic lymphocytic leukemia (CLL) and as monotherapy for relapsed follicular B cell, small lymphocytic lymphoma and indolent non-Hodgkin lymphoma.
  • Idelalisib is an antineoplastic kinase inhibitor used to treat chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL).
  • Idelalisib is a second-line drug for patients whose chronic lymphocytic leukemia (CLL) has relapsed. Used in combination with rituximab,[rx] idelalisib is to be used in patients for whom rituximab alone would be considered appropriate therapy due to other existing medical conditions.[rx] It appears to be effective and leads to improvement of lymphadenopathy and splenomegaly. However, the counts take longer to decrease to normal levels with idelalisib. It is not recommended as a first-line treatment.[rx]
  • It is also approved for the treatment of follicular B-cell non-Hodgkin lymphoma (FL) and relapsed small lymphocytic lymphoma (SLL), both in patients who have received at least two prior systemic therapies.[rx]
  • In combination with rituximab, for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL) for whom rituximab alone would be considered appropriate therapy due to other co-morbidities. The treatment of patients with relapsed follicular B-cell non-Hodgkin lymphoma (FL) who have received at least 2 prior systemic therapies. The treatment of patients with relapsed small lymphocytic lymphoma (SLL) who have received at least 2 prior systemic therapies.
  • Relapsed Chronic Lymphocytic Leukemia
  • Relapsed Small Lymphocytic Lymphoma
  • Relapsed follicular B-cell non-Hodgkin’s lymphoma

Use in Cancer

Idelalisib is approved to treat:

Idelalisib is also being studied in the treatment of other types of cancer.

Contraindications

  • a bad
  • decreased blood platelets
  • low levels of a type of white blood cell called neutrophils
  • a type of of the lung called interstitial pneumonitis
  • a hole in the intestine
  • liver problems
  • high amount of in the blood
  • abnormal liver function tests
  • pregnancy
  • a patient who is producing milk and breastfeeding
  • progressive multifocal leukoencephalopathy, a type of brain infection

Strengths: 100 mg; 150 mg

Non-Hodgkin’s Lymphoma

  • 150 mg orally 2 times a day until or unacceptable toxicity
  • This drug can be taken with or without food.
  • Tablets should be swallowed whole.
  • If the patient misses a dose within 6 hours of the time it is usually taken, the patient should take the missed dose as soon as possible and resume the normal dosing schedule.
  • If a patient misses a dose by more than 6 hours, the patient should not take the missed dose and simply resume the usual dosing schedule.

Chronic Lymphocytic Leukemia

  • 150 mg orally 2 times a day until disease or unacceptable toxicity
  • This drug can be taken with or without food.
  • Tablets should be swallowed whole.
  • If the patient misses a dose within 6 hours of the time it is usually taken, the patient should take the missed dose as soon as possible and resume the normal dosing schedule.
  • If a patient misses a dose by more than 6 hours, the patient should not take the missed dose and simply resume the usual dosing schedule.

Lymphoma

  • 150 mg orally 2 times a day until disease progression or unacceptable toxicity
  • This drug can be taken with or without food.
  • Tablets should be swallowed whole.
  • If the patient misses a dose within 6 hours of the time it is usually taken, the patient should take the missed dose as soon as possible and resume the normal dosing schedule.
  • If a patient misses a dose by more than 6 hours, the patient should not take the missed dose and simply resume the usual dosing schedule.
  • In combination with rituximab, for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL) for whom rituximab alone would be considered appropriate therapy due to other co-morbidities.
  • The treatment of patients with relapsed follicular B-cell non-Hodgkin lymphoma (FL) who have received at least 2 prior systemic therapies.
  • The treatment of patients with relapsed small lymphocytic lymphoma (SLL) who have received at least 2 prior systemic therapies.

Liver Dose Adjustments

  • AST and/or ALT greater than 3 to 5 times the upper limit of normal (3 to 5 x ULN): Maintain dose, monitor at least weekly until less than or equal to ULN.
  • AST and/or ALT greater than 5 to 20 x ULN: Withhold therapy, monitor at least weekly until less than or equal to ULN, may resume at 100 mg twice a day.
  • AST and/or ALT greater than 20 x ULN: Permanently discontinue therapy.
  • Bilirubin greater than 1.5 to 3 x ULN: Maintain dose, monitor at least weekly until less than or equal to ULN.
  • Bilirubin greater than 3 to 10 x ULN: Withhold therapy, monitor at least weekly until less than or equal to ULN, may resume at 100 mg twice a day.
  • Bilirubin greater than 10 x ULN: Permanently discontinue therapy.

Dose Adjustments

Pneumonitis:

  • Discontinue therapy in patients with any severity of symptomatic pneumonitis.

Diarrhea:

  • If diarrhea develops during therapy (increase of 4 to 6 stools per day over ), maintain dose and monitor at least weekly until resolved.
  • If severe diarrhea develops during therapy (increase of 7 or more stools per day over baseline), withhold therapy and monitor at least weekly until resolved, then resume therapy at 100 mg twice a day.
  • If life-threatening diarrhea develops during treatment, discontinue therapy permanently.

:

  • ANC 1 to less than 1.5 Gi/L: Maintain dose.
  • ANC 0.5 to less than 1 Gi/L: Maintain dose and monitor ANC at least weeky.
  • ANC less than 0.5: interrupt therapy and monitor at least weekly until ANC is 0.5 Gi/L or greater, then resume therapy at 100 mg twice a day.

:

  • Platelets 50 to less than 75 Gi/L: Maintain dose.
  • Platelets 25 to less than 50 Gi/L: Maintain dose and monitor counts at least weekly.
  • Platelets less than 25 Gi/L: Withhold therapy and monitor at least weekly; resume therapy at 100 mg twice a day when platelets are 25 Gi/L or greater.

Infections:

  • Grade 3 or higher or : Interrupt therapy until infection has resolved.
  • Evidence of CMV infection or viremia: Interrupt therapy in patients with evidence of active CMV infection of any grade or viremia (positive PCR or antigen test) until the viremia has resolved. If therapy is resumed, monitor patients by PCR or antigen test for CMV reactivation at least monthly.
  • Evidence of PJP infection: Interrupt therapy in patients with suspected PJP infection of any grade. Permanently discontinue therapy if PJP infection is confirmed.

Lymphocytosis:

  • No dose modification is required for lymphocytosis, which has been observed in some patients taking this drug. This lymphocytosis is a pharmacodynamic effect and should not be considered progressive disease in the absence of other clinical findings.

FATAL AND SERIOUS TOXICITIES: HEPATIC, SEVERE DIARRHEA, COLITIS, PNEUMONITIS, INFECTIONS, and INTESTINAL PERFORATION:

  • Fatal and/or serious hepatotoxicity occurred in 16% to 18% of patients. Monitor hepatic function prior to and during therapy. Interrupt therapy and then reduce or discontinue the drug as recommended.
  • Fatal and/or serious and severe diarrhea or colitis occurred in 14% to 20% of patients. Monitor for development of severe diarrhea or colitis. Interrupt therapy and then reduce or discontinue the drug as recommended.
  • Fatal and/or serious pneumonitis occurred in 4% of patients. Monitor for pulmonary symptoms and bilateral interstitial infiltrates. Interrupt therapy and then reduce or discontinue the drug as recommended.
  • Fatal and/or serious infections occurred in 21% to 48% of patients. Monitor for infection. Interrupt therapy if infection is suspected.
  • Fatal and serious intestinal perforation can occur. Discontinue therapy for intestinal perforation.

Administration advice:

  • Take with or without food.
  • Tablets should be swallowed whole.

Side Effects

The Most Common

  • headache
  • difficulty falling asleep or staying asleep
  • decreased appetite
  • increased thirst
  • heartburn
  • joint pain
  • night sweats
  • lack of energy
  • swelling of the hands, feet, ankles, or lower legs
  • red, itching, peeling, or blistering skin
  • painful sores or ulcers on your skin, lips, or in your mouth
  • difficulty swallowing or breathing; swelling of the face, lips, or throat; hives; itching
  • Bloating or swelling of the face, arms, hands, lower legs, or feet
  • decreased appetite
  • difficulty with moving
  • muscle pain or stiffness
  • night sweats
  • pain in the joints
  • rapid weight gain
  • tingling of the hands or feet
  • trouble sleeping
  • unusual weight gain or loss

More common

  • Black, tarry stools
  • body aches or pain
  • chest tightness
  • chills
  • clay colored stools
  • confusion
  • cough
  • cough producing mucus
  • dark urine
  • decreased appetite
  • difficulty with breathing
  • dizziness
  • ear congestion
  • fainting
  • fast heartbeat
  • fever
  • headache
  • itching or skin rash
  • lightheadedness
  • loss of appetite
  • loss of voice
  • lower back or side pain
  • nausea and vomiting
  • pain
  • pain or tenderness around the eyes and cheekbones
  • painful or difficult urination
  • pale skin
  • rapid, shallow breathing
  • sneezing
  • sore throat
  • stomach cramps, pain, or tenderness
  • stuffy or runny nose
  • swelling of the feet or lower legs
  • trouble breathing
  • ulcers, sores, or white spots in the mouth
  • unusual bleeding or bruising
  • unusual tiredness or weakness
  • watery or bloody diarrhea
  • yellow eyes or skin

Rare

  • Bladder pain
  • bloody or cloudy urine
  • difficult, burning, or painful urination
  • frequent urge to urinate
  • lower back or side pain
  • Blistering, peeling, or loosening of the skin
  • chest pain
  • cracks in the skin
  • difficulty with swallowing
  • general feeling of discomfort or illness
  • heartburn
  • hives
  • indigestion
  • joint or muscle pain
  • loss of heat from the body
  • puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
  • red skin lesions, often with a purple center
  • red, irritated eyes
  • red, swollen skin
  • scaly skin
  • severe abdominal or stomach pain, cramping, or burning
  • thickening of bronchial secretions
  • vomiting of material that looks like coffee grounds, severe and continuing

Drug Interactions

Pregnancy and Lactation

FDA Pregnancy Category D

Pregnancy

Based on findings in animals, Zydelig may cause fetal harm when administered to a pregnant woman. Idelalisib was teratogenic in animals. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus.

Lactation

No information is available on the clinical use of idelalisib during breastfeeding. Because idelalisib is more than 84% bound to plasma proteins, the amount in milk is likely to be low. It is sometimes given in combination with rituximab, which may increase the risk to the infant. The manufacturer recommends that breastfeeding be discontinued during idelalisib therapy and for at least 1 month after the last dose.

How should this medicine be used?

Idelalisib comes as a tablet to take by mouth. It is usually taken with or without food twice a day. Take idelalisib at around the same times every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take idelalisib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Swallow the tablets whole; do not split, chew, or crush them.

Your doctor may decrease your dose of idelalisib or tell you to stop taking the medication for a time or permanently if you experience serious side effects during your treatment. This depends on how well the medication works for you and the side effects you experience. Talk to your doctor about how you are feeling during your treatment. Continue to take idelalisib even if you feel well. Do not stop taking idelalisib without talking to your doctor. Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient.

What special precautions should I follow?

Before taking idelalisib,

  • tell your doctor and pharmacist if you are allergic to idelalisib, any other medications, or any of the ingredients in idelalisib tablets. If you have ever had a severe allergic reaction in the past, such as swelling of your face, lips or throat; difficulty swallowing or breathing; or peeling, blistering skin, your doctor will probably tell you not to take idelalisib.Ask your pharmacist or check the Medication Guide for a list of the ingredients.
  • tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: carbamazepine (Carbatrol, Epitol, Equetro, others); clarithromycin (Biaxin, in PrevPac); itraconazole (Onmel, Sporanox); ketoconazole (Nizoral); medications used to treat human immunodeficiency virus (HIV) such as efavirenz (Sustiva, in Atripla), indinavir (Crixivan), nelfinavir (Viracept), nevirapine (Viramune), ritonavir (Norvir, in Kaletra, in Technivie); midazolam; nefazodone; phenobarbital; phenytoin (Dilantin, Phenytek); pioglitazone (Actos, in Actoplus Met, in Duetact, in Oseni); rifabutin (Mycobutin); and rifampin (Rifadin, Rimactane, in Rifamate, in Rifater). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with idelalisib, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.
  • tell your doctor and pharmacist what herbal products you are taking, especially St. John’s wort. You should not take St. John’s wort during your treatment with idelalisib.
  • tell your doctor if you are pregnant, plan to become pregnant, or plan to father a child. You should not become pregnant during your treatment with idelalisib. You should use birth control to prevent pregnancy during your treatment with idelalisib and at least 1 month after your final dose. If you are a male and your partner can become pregnant, you should use effective birth control during your treatment and for 3 months after your final dose. If you or your partner become pregnant while taking idelalisib, call your doctor immediately. Idelalisib may harm the fetus.
  • tell your doctor if you are breastfeeding. You should not breastfeed while you are taking idelalisib and for at least one month after your final dose.

  1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205858lbl.pdf
  2. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/205858s014lbl.pdf
  3. https://pubchem.ncbi.nlm.nih.gov/compound/Idelalisib
  4. https://go.drugbank.com/drugs/DB09054
  5. https://www.drugs.com/mtm/idelalisib.html
  6. https://medlineplus.gov/druginfo/meds/a614040.html
  7. https://en.wikipedia.org/wiki/Idelalisib
  8. https://www.webmd.com/drugs/2/drug-166679/idelalisib-oral/details/list-contraindications
  9. https://www.mayoclinic.org/drugs-supplements/idelalisib-oral-route/side-effects/drg-20112990?p=1
  10. https://www.cancer.gov/about-cancer/treatment/drugs/idelalisib
  11. https://commonchemistry.cas.org/detail?cas_rn=870281-82-6
  12. https://www.nlm.nih.gov/copyright.html
  13. https://chem.nlm.nih.gov/chemidplus/sid/0870281826
  14. https://chem.nlm.nih.gov/chemidplus/sid/1146702546
  15. https://chem.nlm.nih.gov/chemidplus/
  16. https://www.drugbank.ca/legal/terms_of_use
  17. https://www.drugbank.ca/drugs/DB09054
  18. https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources
    https://comptox.epa.gov/dashboard/DTXSID701007266
    https://comptox.epa.gov/dashboard/chemical-lists/
  19. https://echa.europa.eu/web/guest/legal-notice
    https://echa.europa.eu/information-on-chemicals
    https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/244183
  20. https://www.fda.gov/about-fda/about-website/website-policies#linking
    IDELALISIB
    https://gsrs.ncats.nih.gov/ginas/app/beta/substances/YG57I8T5M0
  21. https://pubchem.ncbi.nlm.nih.gov/source/hsdb/8408
  22. http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:82701
    ChEBI Ontology
    http://www.ebi.ac.uk/chebi/userManualForward.do#ChEBI%20Ontology
  23. https://www.fda.gov/about-fda/about-website/website-policies#linking
    IDELALISIB
    https://dailymed.nlm.nih.gov/dailymed/browse-drug-classes.cfm
    https://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm162549.htm
  24. https://www.nlm.nih.gov/copyright.html
    Idelalisib
    https://www.ncbi.nlm.nih.gov/books/n/livertox/Idelalisib/
  25. https://www.cancer.gov/policies/copyright-reuse
    https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C78825
    NCI Thesaurus Tree
    https://ncit.nci.nih.gov
  26. http://www.ebi.ac.uk/Information/termsofuse.html
    https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2216870/
    ChEMBL Protein Target Tree
    https://www.ebi.ac.uk/chembl/g/#browse/targets
  27. http://ctdbase.org/about/legal.jsp
    idelalisib
    https://ctdbase.org/detail.go?type=chem&acc=C552946
  28. http://www.dgidb.org/downloads
    IDELALISIB
    https://www.dgidb.org/drugs/IDELALISIB
  29. https://www.guidetopharmacology.org/about.jsp#license
    idelalisib
    https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6741
    https://www.guidetopharmacology.org/targets.jsp
  30. http://idrblab.net/ttd/data/drug/details/D0J5VR
  31. https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use
    https://clinicaltrials.gov/
  32. https://www.nlm.nih.gov/copyright.html
    IDELALISIB
    https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=IDELALISIB
  33. https://www.ema.europa.eu/en/about-us/legal-notice
    Zydelig (EMEA/H/C/003843)
    https://www.ema.europa.eu/en/medicines/human/EPAR/zydelig
  34. https://www.nlm.nih.gov/copyright.html
    Idelalisib
    https://www.ncbi.nlm.nih.gov/books/NBK500849/
  35. EU Clinical Trials Register
    https://www.clinicaltrialsregister.eu/
  36. https://www.fda.gov/about-fda/about-website/website-policies#linking
    https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
  37. https://www.whocc.no/copyright_disclaimer/
    https://www.whocc.no/atc/
    ATC Code
    https://www.whocc.no/atc_ddd_index/
  38. https://www.fda.gov/about-fda/about-website/website-policies#linking
    Zydelig
    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=medguide.page
  39. https://www.fda.gov/about-fda/about-website/website-policies#linking
    IDELALISIB
    https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory
  40. https://www.cancer.gov/policies/copyright-reuse
    Idelalisib
    https://www.cancer.gov/about-cancer/treatment/drugs/idelalisib
  41. NIPH Clinical Trials Search of Japan
    https://rctportal.niph.go.jp/en/
  42. https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html
    idelalisib
    https://rxnav.nlm.nih.gov/id/rxnorm/1544460
  43. http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/40L
  44. PubChem
    https://pubchem.ncbi.nlm.nih.gov
    https://gitlab.lcsb.uni.lu/eci/pubchem-docs/-/raw/main/pfas-tree/PFAS_Tree.pdf?inline=false
  45. https://www.rcsb.org/pages/policies
    https://www.rcsb.org/
  46. Springer Nature
    https://pubchem.ncbi.nlm.nih.gov/substance/?source=15745&sourceid=31052090-329671522
    https://pubchem.ncbi.nlm.nih.gov/substance/?source=15745&sourceid=31052090-329667227
  47. https://creativecommons.org/licenses/by-nc-nd/4.0/
    https://pubchem.ncbi.nlm.nih.gov/substance/?source=22163&sourceid=31052090-329667578
    https://pubchem.ncbi.nlm.nih.gov/substance/?source=22163&sourceid=31052090-826201670
  48. https://creativecommons.org/publicdomain/zero/1.0/
    Idelalisib
    https://www.wikidata.org/wiki/Q5908266
  49. https://www.nlm.nih.gov/copyright.html
    idelalisib
    https://www.ncbi.nlm.nih.gov/mesh/67552946
    MeSH Tree
    http://www.nlm.nih.gov/mesh/meshhome.html
    Antineoplastic Agents
    https://www.ncbi.nlm.nih.gov/mesh/68000970
    Enzyme Inhibitors
    https://www.ncbi.nlm.nih.gov/mesh/68004791
  50. https://www.kegg.jp/kegg/legal.html
    USP drug classification
    http://www.genome.jp/kegg-bin/get_htext?br08302.keg
    http://www.genome.jp/kegg-bin/get_htext?br08303.keg
    Target-based classification of drugs
    http://www.genome.jp/kegg-bin/get_htext?br08310.keg
    Drug Groups
    http://www.genome.jp/kegg-bin/get_htext?br08330.keg
  51. http://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html
  52. https://creativecommons.org/licenses/by/4.0/
    https://www.norman-network.com/nds/SLE/
  53. PATENTSCOPE (WIPO)
    SID 391539868
    https://pubchem.ncbi.nlm.nih.gov/substance/391539868
    SID 427295427
    https://pubchem.ncbi.nlm.nih.gov/substance/427295427

RX Medical Knowledge Graph

Explore this medical topic

Continue through verified related conditions, investigations, medicines, and patient guides. These links are educational and do not replace professional medical advice.

Related medical topics

Carbapenem - Uses, Dosage, Side Effects, Interactions83% relationship confidence COVID‑19 Vaccine - Uses, Dosage, Side Effects, Interactions83% relationship confidence Dosage of Filgrastim - Side Effects, Interaction83% relationship confidence Estrogen Drug - Uses, Dosage, Side Effects, Interaction83% relationship confidence Filgrastim - Uses, Dosage, Side Effects, Interaction83% relationship confidence Lipegfilgrastim - Uses, Dosage, Side Effects, Interaction83% relationship confidence Meropenem - Uses, Dosage, Side Effects, Interactions83% relationship confidence What Is Antacids? -Uses, Dosage, Side Effects, Interaction83% relationship confidence
More from this topic
  1. Vasodilator Drugs

    Vasodilator drugs relax and widen blood vessels, increasing blood flow. A few examples include ACE inhibitors, ARBs, calcium channel blockers, and nitrates.   DefinitionVasodilators are medicines that dilate...

    June 9, 2025 • Drugs (A - Z)
  2. Methamphetamine Hydrochloride – Uses, Dosage, Side Effects, Interaction

    Methamphetamine Hydrochloride is the hydrochloride salt form of methamphetamine, an amphetamine and sympathomimetic amine with CNS stimulating properties. Methamphetamine hydrochloride acts by facilitating the release of catecholamines, particularly noradrenaline and dopamine, from...

    June 5, 2025 • Drugs (A - Z)
  3. Methamphetamine – Uses, Dosage, Side Effects, Interactions

    Methamphetamine is a member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent. It has a role as a neurotoxin, a psychotropic drug,...

    June 5, 2025 • Drugs (A - Z)
  4. Vitamin D3 – Uses, Dosage, Side Effects, Interactions

    DefinitionCholecalciferol is a steroid? hormone produced in the skin when exposed to ultraviolet light or obtained from dietary sources. The active form of cholecalciferol, 1,25-dihydroxycholecalciferol (calcitriol) plays an important role...

    March 10, 2025 • Drugs (A - Z)
  5. Imidazole – Uses, Dosage, Side Effects, Interactions

    DefinitionImidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is...

    October 20, 2023 • Drugs (A - Z)
  6. Carbimazole

    Carbimazole is a member of the class of imidazoles that is methimazole in which the nitrogen-bearing hydrogen is converted into its methoxycarbonyl derivative. A prodrug for methimazole, carbimazole is...

    October 20, 2023 • Drugs (A - Z)
  7. Methylthiouracil – Uses, Dosage, Side Effects, Interactions

    DefinitionA thiourea antithyroid agent that inhibits the synthesis of thyroid? hormone. It is used in the treatment of hyperthyroidism?. Methylthiouracil is an organosulfur compound that is used in...

    October 20, 2023 • Drugs (A - Z)
  8. Propylthiouracil – Uses, Dosage, Side Effects, Interactions

    DefinitionPropylthiouracil is a Thyroid? Hormone Synthesis Inhibitor. The mechanism of action of propylthiouracil is as a Thyroid Hormone Synthesis Inhibitor. 6-propyl-2-thiouracil is a pyrimidine-thione consisting of uracil in which the...

    October 20, 2023 • Drugs (A - Z)
  9. Methimazole

    DefinitionMethimazole ( Metirox 5 and 10 mg) is a member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen that is attached to...

    October 20, 2023 • Drugs (A - Z)
  10. Mirogabalin – Uses, Dosage, Side Effects, Interactions

    DefinitionMirogabalin has been used in trials studying the treatment of Post-herpetic Neuralgia?, Pain? Associated With Fibromyalgia?, and Diabetic peripheral neuropathic pain. Mirogabalin is a medication designed...

    August 12, 2023 • Drugs (A - Z)
RX Clinical Pathway Engine

Continue through a complete learning pathway

Move from understanding the topic to symptoms, tests, treatment, medicines, monitoring, and prevention.

Search the complete library
  1. Understand the condition Begin with the essential facts and a clear explanation of the topic.
  2. Recognize symptoms Learn common symptoms, signs, and patterns of presentation.
  3. Know when to seek help Review urgent warning signs and when professional assessment may be needed.
  4. Understand causes and risks Explore causes, risk factors, mechanisms, and contributing conditions.
  5. Explore tests and diagnosis Learn how clinicians assess the condition and which investigations may be discussed.
  6. Learn treatment approaches Review general treatment categories and management principles.
  7. Understand medicines safely Continue to medicine education, uses, precautions, and monitoring.
  8. Plan monitoring and follow-up Understand monitoring, complications, rehabilitation, and follow-up learning.
  9. Review prevention and self-care Explore prevention, healthy routines, and questions to discuss with a clinician.

Conditions & Diseases

Background, symptoms, causes, diagnosis, and care.

Explore this library

Tests & Investigations

Laboratory, imaging, screening, and diagnostic education.

Explore this library

Medicines

Uses, safety, monitoring, and related medicine knowledge.

Explore this library

Cancer Knowledge

Cancer types, screening, oncology, and treatment education.

Explore this library
Doctor visit helper

Prepare before seeing a doctor

A simple rural-patient checklist to help you explain symptoms clearly, ask better questions, and avoid unsafe self-treatment.

Safety note: This is not a prescription or diagnosis. For severe symptoms, pregnancy danger signs, children with serious illness, chest pain, breathing difficulty, stroke-like weakness, or major injury, seek urgent care.

Which doctor may help?

Start with a registered doctor or the nearest qualified health center.

What to tell the doctor

  • Write when the problem started and how it changed.
  • Bring old prescriptions, investigation reports, and current medicines.
  • Write allergies, pregnancy status, diabetes, kidney/liver disease, and major past illnesses.
  • Bring one family member if the patient is weak, elderly, confused, or a child.

Questions to ask

  • What is the most likely cause of my symptoms?
  • Which danger signs mean I should go to hospital quickly?
  • Which tests are necessary now, and which can wait?
  • How should I take medicines safely and what side effects should I watch for?
  • When should I come for follow-up?

Tests to discuss

  • Vital signs: temperature, pulse, blood pressure, oxygen saturation
  • Basic physical examination by a clinician
  • CBC, urine test, blood sugar, or imaging only when clinically needed

Avoid these mistakes

  • Do not use antibiotics, steroid tablets/injections, or strong painkillers without proper medical advice.
  • Do not hide pregnancy, kidney disease, ulcer, allergy, or blood thinner use.
  • Do not delay emergency care when danger signs are present.

Medicine safety and first-aid guide

This section is for patient education only. It does not replace a doctor, pharmacist, or emergency care.

Safe first steps

  • Avoid heavy lifting, sudden bending, and prolonged bed rest.
  • Use comfortable posture and gentle movement as tolerated.
  • Discuss physiotherapy, X-ray, or MRI only when clinically needed.

OTC medicine safety

  • For mild back pain, pain-relief medicine may be discussed with a doctor or pharmacist.
  • Avoid repeated painkiller use if you have kidney disease, stomach ulcer, uncontrolled blood pressure, or are taking blood thinners.

Avoid these mistakes

  • Do not start antibiotics without a proper medical decision.
  • Do not use steroid tablets or injections casually for quick relief.
  • Do not delay emergency care because of home remedies.

Get urgent help if

  • Back pain with leg weakness, numbness around private area, loss of urine/stool control, fever, cancer history, or major injury needs urgent care.
Medicine names, dose, and timing must be decided by a qualified clinician or pharmacist after checking age, pregnancy, allergy, other diseases, and current medicines.

For rural patients and family caregivers

Patient health record and symptom diary

Write your symptoms, medicines already taken, test results, and questions before visiting a doctor. This note stays on your device unless you print or copy it.

Doctor to discuss: Medicine doctor / pediatrician for children / qualified clinician
Tests to discuss with doctor
  • Temperature chart and hydration assessment
  • CBC with platelet count if fever persists or dengue/other infection is possible
  • Urine test, malaria/dengue tests, chest evaluation, or blood culture only when clinically indicated
Questions to ask
  • What is the most likely cause of my symptoms?
  • Which warning signs mean I should go to emergency care?
  • Which tests are really needed now?
  • Which medicines are safe for my age, pregnancy status, allergy, kidney/liver/stomach condition, and current medicines?
  • Do I need antibiotics, or is this more likely viral?

Emergency warning signs such as chest pain, severe breathing difficulty, sudden weakness, confusion, severe dehydration, major injury, or loss of bladder/bowel control need urgent medical care. Do not wait for online information.

Safe pathway to proper treatment

Care roadmap for: Idelalisib – Uses, Dosage, Side Effects, Interation

Use this simple roadmap to understand the next safe steps. It is educational and does not replace examination by a doctor.

Go to emergency care if you notice:
  • Severe or rapidly worsening symptoms
  • Breathing difficulty, chest pain, fainting, confusion, severe weakness, major injury, or severe dehydration
Doctor / service to discuss: Qualified healthcare provider; specialist depends on symptoms and examination.
  1. Step 1

    Check danger signs first

    If danger signs are present, seek emergency care and do not wait for online information.

  2. Step 2

    Record the symptom story

    Write when symptoms started, severity, medicines already taken, allergies, pregnancy status, and test results.

  3. Step 3

    Visit a qualified clinician

    A doctor, nurse, or qualified healthcare provider can examine you and decide which tests or treatment are needed.

  4. Step 4

    Do only useful tests

    Do tests after clinical assessment. Avoid unnecessary tests, random antibiotics, or repeated medicines without diagnosis.

  5. Step 5

    Follow up and return early if worse

    If symptoms worsen, new warning signs appear, or treatment is not helping, return for review quickly.

Rural patient practical tips
  • Take a written symptom diary and all previous prescriptions/test reports.
  • Do not hide medicines already taken, even herbal or over-the-counter medicines.
  • Ask which warning signs mean urgent referral to hospital.

This roadmap is for education. A real diagnosis and treatment plan requires history, examination, and clinical judgment.